These results are consistent with recent studies reporting that AG490 inhibits Jak1 activated by IL-6 in myeloma cells or IL-2-induced Jak3 activity in an IL-2-dependent T-cell line [17,35], suggesting that the aforementioned three Jak proteins share AG490 sensitivity. Here, IL6 is linked to plasma cell myeloma.